Company: CERO
Filing Date: 2025-05-02
Form Type: PRER14A
Source: 0001213900-25-039149
Chunk: 129

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-02
Form: PRER14A
Chunk 129
---
 in this proxy statement under the section “Security Ownership of Certain Beneficial Owners and Management.” (2)Daniel Corey served as the Chief Technology Officer and a member of the board of directors from February 2024 to September 2024, and previously served as Chief Executive Officer, Chief Scientific Officer, and a member of the board of directors of Legacy CERo until the closing of the Business Combination in February 2024. (3)Brian G. Atwood served as Chairman and Chief Executive Officer from February 2024 to September 2024, and previously served as Chairman of PBAX until the closing of the Business Combination in February 2024 Mr. Atwood is a member of the board of directors and serves as a trustee of Atwood -EdminsterTrust dtd 4 -2-2000. (4)Chris Ehrlich has served as the Chairman and Chief Executive Officer since December 2024, and previously served as (i) interim Chairman and Chief Executive Officer from October 2024 to November 2024, (ii) Vice Chairman of the board of directors from February 2024 to September 2024, and (iii) the Chief Executive Officer of PBAX until the closing of the Business Combination in February 2024. (5)Phoenix Biotech Sponsor, LLC beneficially owned more than 5% of our outstanding capital stock at the time of the transaction.

73 Registered Direct Offering in February 2025 On February 7, 2025, we issued and sold 300,000shares of our Common Stock and 2,251,020 Pre -FundedWarrants to purchase 2,251,020shares of our Common Stock together with 2,551,020 February 2025 Common Warrants to purchase 2,551,020shares of Common Stock. Each share of Common Stock or Pre -FundedWarrant is being sold together with a February 2025 Common Warrant to purchase one share of Common Stock. The shares of Common Stock or Pre -FundedWarrants and accompanying February 2025 Common Warrants were issued separately and were immediately separable upon. Brian Atwood, one of our directors, purchased an aggregate of 510,200 Pre -FundedWarrants and accompanying February 2025 Common Warrants to purchase 510,200shares of Common Stock for a total purchase price of approximately $1 million at this offering. Policies and Procedures for Related Party Transactions We have adopted a code of conduct and ethics requiring us to avoid,